INTRODUCTION
============

Lower urinary tract symptoms (LUTS) are classified as storage symptoms, urinary symptoms, and postvoiding symptoms. Recent epidemiologic data have revealed that more than 64% of men over 40 years of age have at least 1 LUTS \[[@b1-inj-1834982-491]\]. These symptoms impair the quality of life of elderly individuals and may lead to falls, skin infections, sleep disorders, and depression \[[@b2-inj-1834982-491]\].

Among LUTS, storage symptoms are predominant (51%), followed by voiding (26%) and postvoiding symptoms (17%), which are especially problematic.

The most common disease criterion is overactive bladder (OAB), which is characterized by urinary frequency, urgency, nocturia, and urge incontinence. OAB is usually due to detrusor instability \[[@b3-inj-1834982-491]\]. OAB occurs for various reasons, such as pregnancy, aging, childbirth, and infection, and may originate from neurologic problems such as those induced by diabetes mellitus (DM) or problems in the central nervous system \[[@b4-inj-1834982-491]\].

DM affects many organs, resulting in many complications, the most important of which in urology is urinary bladder dysfunction due to diabetes \[[@b5-inj-1834982-491]\].

Animal experimental studies have consistently shown that the induction of diabetes markedly affects the morphology, innervation, and function of the urinary bladder \[[@b6-inj-1834982-491],[@b7-inj-1834982-491]\]. Studies have revealed that more than 80% of patients with diabetes have LUTS. Considering that 60% and 50% of patients with diabetes have neuropathy and renal complications, respectively, we can infer that DM exerts considerable effects on voiding function \[[@b8-inj-1834982-491],[@b9-inj-1834982-491]\].

DM bladder dysfunction refers to LUTS caused by DM, and it is characterized by decreased bladder sensation (bladder bloating), increased bladder sensitivity with inadequate contraction, decreased bladder contraction, and increased residual urine \[[@b10-inj-1834982-491],[@b11-inj-1834982-491]\].

Although the medical use of anticholinergics for general OAB has gained universal acceptance, there is little specific motivation for its use in the treatment of DM-related bladder dysfunction, other than for idiopathic OAB.

Although DM-related bladder dysfunction is not a lifethreatening disease, it has a serious negative impact on quality of life, with a relatively high prevalence of 32%--45% \[[@b12-inj-1834982-491],[@b13-inj-1834982-491]\]. LUTS can affect people of all ages, and their complications related to diabetes may be exacerbated during the aging process, resulting in a huge socioeconomic burden.

In this study, we compared the effects of solifenacin treatment on the improvement of LUTS between patients with idiopathic OAB and patients with OAB and DM.

MATERIALS AND METHODS
=====================

From January 2012 to January 2014, we conducted a multicenter, prospective, parallel-group, open-label, 12-week study. Subjects included women aged 20--65 years who had experienced OAB symptoms for more than 3 months with an Overactive Bladder Symptom Score (OABSS) subscore for the third question of ≥2, a total OABSS of ≥3, and a \>8 total micturition events per day on average during 3 days according to a voiding diary or at least 1 episode of urgent urinary incontinence. The DM patients that were included in the study were diagnosed by an endocrinologist and were under proper medical control.

Exclusion criteria were uncontrolled *de novo* DM, a urinary peak flow rate of \<12 mL/sec, PVR of \>20% of the voided urine or \>120 mL, having undergone urologic surgery (including procedures for stress incontinence, cystitis, and pelvic prolapse) within the past 6 months, having undergone bladder training, or having taken an anticholinergic medication within the past 3 months.

Patients who took medications that could affect bladder function (anticholinergics, sympathomimetics, sympatholytics, calcium channel blockers, narcotics, antidepressants, antipsychotics, and diuretics) and patients with urinary tract infections, interstitial cystitis, bladder stones, past pelvic radiotherapy, or a history of malignant disease were also excluded.

All subjects were assigned to the DM OAB group or the idiopathic OAB group according to their medical history. The study process is shown in [Fig. 1](#f1-inj-1834982-491){ref-type="fig"}.

All patients received 5 mg of solifenacin once daily. Patients were allowed to increase or maintain their dose based on the choices made by the patients and their physicians regarding symptom improvement and tolerability.

The efficacy and adverse effects of solifenacin treatment were evaluated in the DM OAB and idiopathic OAB groups at the beginning of the study and at 4 and 12 weeks after the start of the study.

Changes in the average number of voiding times and number of urgency episodes were assessed by 3-day records of urination. Voiding diary records encompassing \>2 days within 3 days were regarded as valid. Changes in clinical parameters such as the OABSS, urgency, urinary urgency incontinence, nocturia, frequency according to a voiding diary, uroflowmetry, and PVR at the first visit (V1), week 4 (V2), and week 12 (V3) were compared using descriptive analyses.

All values are expressed as mean with standard deviation. The significance of differences between the DM OAB and idiopathic OAB groups was determined using the Student t-test and repeated-measures analysis of variance, with differences considered significant at P\<0.05. All statistical analyses were performed using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

[Fig. 1](#f1-inj-1834982-491){ref-type="fig"} shows the reasons for participant drop-out in the present study. Among the 241 patients eligible for enrollment, 201 completed the study. The DM OAB group comprised 66 participants and the idiopathic OAB group contained 135.

There were no significant differences between the groups in baseline patient characteristics, including age, OABSS, and clinical parameters ([Table 1](#t1-inj-1834982-491){ref-type="table"}).

The idiopathic OAB group showed improvements in urgency, urinary urgency incontinence, nocturia, frequency according to a voiding diary, and incontinence between V1 and V2 and between V1 and V3 with solifenacin treatment ([Table 2](#t2-inj-1834982-491){ref-type="table"}). No changes were found in any other parameters ([Fig. 2](#f2-inj-1834982-491){ref-type="fig"}).

The DM OAB group also demonstrated improvements in urgency, urinary urgency incontinence, frequency according to a voiding diary, and incontinence between V1 and V2 and between V1 and V3 ([Fig. 2](#f2-inj-1834982-491){ref-type="fig"}).

Urgency significantly improved from 3.71 to 2.09, and urinary urgency incontinence also improved from 0.47 to 0.23 in the DM OAB group between V2 and V3 ([Fig. 2A](#f2-inj-1834982-491){ref-type="fig"}, [B](#f2-inj-1834982-491){ref-type="fig"}).

Furthermore, there were no significant differences between the DM OAB group and idiopathic OAB group at each visit. Only urgency and urinary urgency incontinence at V2 showed a statistically significant difference (3.71 vs. 2.28 and 0.47 vs. 0.32) ([Fig. 2A](#f2-inj-1834982-491){ref-type="fig"}, [B](#f2-inj-1834982-491){ref-type="fig"}).

DISCUSSION
==========

DM is generally considered a specific risk factor for voiding dysfunction. Prior studies have demonstrated contradictory outcomes regarding the relationship between DM and OAB \[[@b14-inj-1834982-491]\].

In a previous study, detrusor overactivity was observed in 38.5% of DM patients and various urodynamic findings were observed \[[@b15-inj-1834982-491]\]. In another report, the overall prevalence of OAB in DM patients was as high as 24.8%, and OAB increased with aging and duration of diabetes \[[@b16-inj-1834982-491]\]. Several studies also showed positive associations with age, but other factors, such as body mass index or metabolic syndrome, did not contribute to the development of OAB \[[@b17-inj-1834982-491],[@b18-inj-1834982-491]\].

Furthermore, Palleschi et al. \[[@b19-inj-1834982-491]\] found that OAB was more common in patients with DM, but there was no statistically significant difference in the OAB-questionnaire scores and glycosylated hemoglobin levels in DM patients.

Among the OAB symptoms, urgency was more frequently observed in patients with DM (28.0%) than in those without DM (16.3%) \[[@b20-inj-1834982-491]\]. Men with DM had worse OABSS and International Prostate Symptom Scores than controls, especially for storage domain symptoms because of their higher frequency and nocturia subscores \[[@b21-inj-1834982-491]\]. Consequently, it is evident that OAB, including storage symptoms, is associated with DM \[[@b20-inj-1834982-491]\].

Some hypotheses have been proposed to explain the association between DM and OAB. First, hyperglycemia induces hyperosmolality, causing polydipsia and polyuria; then, the typical storage symptoms of frequency and nocturia result from DM.

Storage symptoms may be explained by the influence of chronic DM on the nervous system via forms of neuropathy. Altered glucose metabolism and tissue ischemia via superoxideinduced free-radical creation and damage to the axonal transport system are all possible mechanisms through which DM leads to peripheral neuropathy \[[@b22-inj-1834982-491]\]. Due to injuries to the parasympathetic and, most likely, sympathetic nerve denervation of the detrusor muscle, deterioration of contraction and compliance can be predicted \[[@b23-inj-1834982-491],[@b24-inj-1834982-491]\].

DM is a significant risk factor for atherosclerosis with consequent organ ischemia, which also induces detrusor overactivity. Isolated bladder muscle strips from rats with DM demonstrated impulsive muscle contractility that was not observed in normal rat bladder, and the bladder tissues from the rats with DM were supersensitive to synthetic cholinergics, even though there was no alteration in the maximum response to carbachol \[[@b25-inj-1834982-491]\].

Regarding atherosclerosis, both central and peripheral mechanisms may be involved in the occurrence of OAB in DM patients. Via DM-related atherosclerotic vasculopathy, multiple cerebral infarctions and bladder ischemia could take place, inducing detrusor overactivity and increased bladder sensation as a result of central and peripheral nerve injuries \[[@b26-inj-1834982-491]\]. Another possible mechanism is based on inflammation. DM may cause tissue inflammation that enhances fibrosis in the urinary tract, eventually inducing LUTS.

Considering the physiological changes associated with DM, it is important to understand how DM patients with OAB respond to OAB management. In general, anticholinergic medications are the cornerstone of OAB management \[[@b27-inj-1834982-491]\]. From the histologic and physiological changes in the diabetic bladder, we can infer that OAB patients with DM experience more LUTS and associated difficulties than those without concomitant DM.

However, few studies have investigated the difference between DM-associated OAB and other OAB types. In a previous study of the effects of darifenacin, a representative muscarinic antagonist, the treatment responses were slightly but significantly smaller in DM patients than in controls, but the differences were only small relative to the overall treatment effect. Furthermore, tolerability and side effects were similar between the 2 groups \[[@b28-inj-1834982-491]\].

The present study also revealed that anticholinergics are equally effective, irrespective of the presence of DM. The DM OAB group showed improvements in urgency, urge incontinence, and night frequency equivalent to those observed in the idiopathic OAB group.

The role of diabetes in voiding dysfunction may be explained by DM-related bladder hypertrophy and dysfunction, which may manifest differentially over time, as contractility and responsiveness to contractile stimuli appear to increase in diabetic bladder smooth muscle at early time points, and this trend can turn into hyporesponsiveness in late stages of the disease over time. However, this is manageable upon normalization of blood glucose via treatment and appropriate medical control \[[@b29-inj-1834982-491]-[@b31-inj-1834982-491]\].

Despite concerns regarding DM-related pathologic changes in the bladder, we observed that anticholinergics could control OAB in patients with well-controlled DM. Most of the patients in our study had well-controlled diabetes because we excluded cases of uncontrolled *de novo* DM.

The patients in the DM OAB group showed a more delayed therapeutic response, because urgency and urge incontinence also improved between V2 and V3 in the DM OAB group, with distinct differences in urgency and urge incontinence at V2 between the DM OAB group and the idiopathic OAB group. We may thus infer that DM patients take longer to respond to OAB medication, possibly because of the negative physiological effects of DM.

Of note, our multicenter study was the first to differentiate a serial change in the response to anticholinergics in DM OAB and idiopathic OAB patients.

However, the study had some limitations because the OAB diagnosis in the clinical setting was not derived from the demonstration of detrusor overactivity through urodynamic tests. Moreover, only data collected from a voiding diary and self-reported OABSS questionnaires were available, although there are other useful parameters in this field. Comorbid factors, excluding diabetes that may have affected voiding function and urine volume were not analyzed. Systemic parameters, such as high blood pressure, stroke, hypertension, obesity, albuminuria, high creatinine levels, a low glomerular filtration rate, and lower hemoglobin levels, are risk factors for LUTS \[[@b32-inj-1834982-491]-[@b34-inj-1834982-491]\]. More importantly, no related analysis was conducted between OAB symptoms and parameters relevant to diabetes, such as the sufficiency of diabetes management as assessed using hemoglobin A1c levels. Data on the duration of DM morbidity and the severity of DM were also lacking. Because of the limited nature of our study, we could not reach definitive conclusions on the absolute efficacy or tolerability of anticholinergics in OAB patients with DM.

However, this study provides some information on the response to a muscarinic receptor antagonist in patients with diabetes versus those without diabetes. We may conclude that a muscarinic receptor antagonist has equivalent efficacy and tolerability for the treatment of OAB patients with and without concomitant diabetes. Larger, well-designed studies should provide more detailed analyses, while taking into account patients' diabetes-related history to identify better methods to control OAB in patients with DM.

In conclusion, patients who received solifenacin demonstrated improved urgency, urge incontinence, nocturia, frequency according to a voiding diary, and incontinence. Management with solifenacin was equally effective for both DM-related OAB and idiopathic OAB.
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![Flow diagram of the study. DM, diabetes mellitus; OAB, overactive bladder; V2, week 4 (visit 2); V3, week 12 (visit 3).](inj-1834982-491f1){#f1-inj-1834982-491}

![Serial changes parameters in diabetes mellitus-associated overactive bladder (DM OAB) and idiopathic OAB at each time point. (A) Urgency. (B) Urge incontinence. (C) Frequency. (D) Night frequency. V1, first visit (visit 1); V2, week 4 (visit 2); V3, week 12 (visit 3). ^a)^P\<0.05, V1 vs. V2. ^b)^P\<0.05, V1 vs. V3. ^c)^P\<0.05, V2 vs. V3. ^d)^P\<0.05, DM OAB vs. idiopathic OAB.](inj-1834982-491f2){#f2-inj-1834982-491}

###### 

Baseline characteristics in the 2 groups

  Characteristic                 DM OAB (n = 66)   Idiopathic OAB (n=135)   P-value
  ------------------------------ ----------------- ------------------------ ---------
  Age (yr)                       55.8 ± 6.9        55.5 ± 7.1               0.96
  OABSS total                    5.23 ± 2.4        5.01 ± 2.2               0.53
  Urgency                        6.60 ± 4.1        5.59 ± 3.7               0.56
  Urinary urgency incontiennce   1.02 ± 0.4        0.89 ± 0.3               0.62
  Frequency                      8.61 ± 2.4        8.82 ± 2.5               0.88
  Nocturia                       1.76 ± 0.9        1.59 ± 0.9               0.23
  Qmax (mL/sec)                  19.83 ± 9.6       18.01 ± 7.6              0.42
  PVR (mL)                       16.73 ± 4.1       18.38 ± 4.5              0.19

Values are presented as mean±standard deviation.

DM, diabetes mellitus; OAB, overactive bladder; OABSS, Overactive Bladder Symptom Score; Qmax, maximum flow rate; PVR, postvoid resirual urine.

###### 

Comparision of follow-up visit results between DM OAB group and idiopathic OAB group

  Variable                       V2                                                                                                                                                             V3                                                                                                                            
  ------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------------
  OABSS Total                    3.23 ± 1.2^[a)](#tfn1-inj-1834982-491){ref-type="table-fn"}^                                                                                                   3.16 ± 1.4^[a)](#tfn1-inj-1834982-491){ref-type="table-fn"}^   3.01 ± 0.9^[b)](#tfn2-inj-1834982-491){ref-type="table-fn"}^   2.89 ± 1.1^[b)](#tfn2-inj-1834982-491){ref-type="table-fn"}^
  Urgency                        3.71 ± 2.1^[a](#tfn1-inj-1834982-491){ref-type="table-fn"},[c](#tfn3-inj-1834982-491){ref-type="table-fn"},[d)](#tfn4-inj-1834982-491){ref-type="table-fn"}^   2.28 ± 1.7^[a)](#tfn1-inj-1834982-491){ref-type="table-fn"}^   2.09 ± 1.8^[b)](#tfn2-inj-1834982-491){ref-type="table-fn"}^   1.77 ± 0.9^[b)](#tfn2-inj-1834982-491){ref-type="table-fn"}^
  Urinary urgency incontiennce   0.47 ± 0.2^[a](#tfn1-inj-1834982-491){ref-type="table-fn"},[c](#tfn3-inj-1834982-491){ref-type="table-fn"},[d)](#tfn4-inj-1834982-491){ref-type="table-fn"}^   0.32 ± 0.1^[a)](#tfn1-inj-1834982-491){ref-type="table-fn"}^   0.23 ± 0.1^[b)](#tfn2-inj-1834982-491){ref-type="table-fn"}^   0.27 ± 0.1^[b)](#tfn2-inj-1834982-491){ref-type="table-fn"}^
  Frequency                      7.01 ± 5.5^[a)](#tfn1-inj-1834982-491){ref-type="table-fn"}^                                                                                                   5.98 ± 3.4^[a)](#tfn1-inj-1834982-491){ref-type="table-fn"}^   6.33 ± 3.7^[b)](#tfn2-inj-1834982-491){ref-type="table-fn"}^   5.70 ± 2.3^[b)](#tfn2-inj-1834982-491){ref-type="table-fn"}^
  Nocturia                       1.36 ± 0.1^[a)](#tfn1-inj-1834982-491){ref-type="table-fn"}^                                                                                                   1.24 ± 0.4^[a)](#tfn1-inj-1834982-491){ref-type="table-fn"}^   1.15 ± 0.4^[b)](#tfn2-inj-1834982-491){ref-type="table-fn"}^   0.85 ± 0.3^[b)](#tfn2-inj-1834982-491){ref-type="table-fn"}^
  Qmax (mL/sec)                  15.26 ± 6.5                                                                                                                                                    15.14 ± 6.4                                                    13.86 ± 6.7                                                    12.76 ± 6.3
  PVR (mL)                       27.43 ± 18.1                                                                                                                                                   29.97 ± 19.4                                                   32.74 ± 14.4                                                   36.36 ± 17.3

Values are presented as mean±standard deviation.

DM, diabetes mellitus; OAB, overactive bladder; OABSS, Overactive Bladder Symptom Score; Qmax, maximum flow rate; PVR, postvoid resirual urine; V1, first visit (visit 1); V2, week 4 (visit 2); V3, week 12 (visit 3).

P\<0.05, V1 vs. V2.

P\<0.05, V1 vs. V3.

P\<0.05, V2 vs. V3.

P\<0.05, DM OAB vs. idiopathic OAB.

The results of V1 is expressed in [Table 1](#t1-inj-1834982-491){ref-type="table"}.
